CYBN
Cybin, Inc. · AMEX
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website cybin.com
- Employees(FY) 50
- ISIN CA23256X4075
Performance
-4.28%
1W
-12.64%
1M
+12.27%
3M
-7.02%
6M
-38.32%
YTD
-35.16%
1Y
Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
Technical Analysis of CYBN 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-09 18:30
- 2024-12-03 18:30
- 2024-11-17 18:00
- 2024-11-13 18:30
- 2024-11-12 18:30
- 2024-10-30 19:30
- 2024-10-23 19:30
- 2024-10-02 19:30
- 2024-09-30 19:30
- 2024-09-23 19:30
- 2024-09-19 17:38
- 2024-09-18 19:26
- 2024-09-03 19:55
- 2024-08-27 07:01
- 2024-08-12 19:30
- 2024-08-07 19:36
- 2024-08-06 19:30
- 2024-07-07 20:38
- 2024-06-27 00:00
What Makes Cybin Inc. (CYBN) a New Buy Stock(Yahoo Finance)
- 2024-06-25 19:41
- 2024-06-18 19:30
- 2024-06-10 21:35
- 2024-06-10 19:30
- 2024-05-28 19:30
- 2024-05-13 19:30
- 2024-05-05 20:32
- 2024-04-24 19:30
- 2024-04-17 19:30
- 2024-04-15 19:30
- 2024-04-09 19:30
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.